证券代码：000953 证券简称： 河化股份 公告编号：2023-032 广西河池化工股份有限公司 关于股东股份减持计划期限届满的公告 股东何建国先生、何卫国先生保证向本公司提供的信息内容真实、准确、完 整，没有虚假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 证券代码：000953 证券简称： 河化股份 公告编号：2023-032 广西河池化工股份有限公司（以下简称"公司"）于 2023 年 2 月 28 日披露 了《关于合计持股 5%以上股东股份减持计划期限届满暨下期减持计划预披露公 告》（公告编号：2023-005），合计持股 5%以上股东及其一致行动人何建国先生、 何卫国先生计划自上述公告披露之日起 15 个交易日后的 6 个月内通过集中竞价 交易合计减持公司股份不超过 7,322,444 股，占公司总股本比例不超过 2%。 2023 年 6 月 22 日，公司披露了《关于股东减持股份时间过半暨减持股份进 展公告》（公告编号：2023-023）。具体内容详见公司指定信息披露媒体《中国证 券报》、《证券时报》和巨潮资讯网（www.cninfo.com. ...

国浩律师（南宁）事务所 关于广西河池化工股份有限公司 2023 年第一次临时股东大会的法律意见书 国浩律师（南宁）意字（2023）第 5048-1 号 致：广西河池化工股份有限公司 国浩律师（南宁）事务所受广西河池化工股份有限公司（以下简称"公 司"）的委托，指派李长嘉、廖乃安律师（以下简称"本律师"）对公司 2023年第一次临时股东大会（以下简称"本次股东大会"或"本次会议"） 召开的全过程进行见证并出具法律意见。 法律意见书 为出具法律意见，本律师审查了公司提供的有关会议文件、资料，公 司保证已向本律师提供了出具法律意见所必须的、真实的书面材料。 基于对上述文件、资料的审查和见证情况，本律师根据《中华人民共 和国公司法》《中华人民共和国证券法》《上市公司股东大会规则》《广 西河池化工股份有限公司章程》（以下简称"《公司章程》"）等有关规 定，按照律师行业公认的业务标准、道德规范和勤勉尽责的精神，对本次 股东大会发表法律意见。 本律师同意公司将本法律意见书与本次股东大会会议决议一同公告， 并依法对法律意见书承担法律责任。 具体法律意见如下： 一、本次股东大会的召集、召开程序 本次会议由公司董事会召集，采取现 ...

广西河池化工股份有限公司 2023 年第一次临时股东大会决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或者重大遗漏。 特别提示： 1、本次股东大会召开期间无增加、修改提案的情况，不存在否决提案的情 况； 2、本次股东大会不存在变更以往股东大会已通过的决议的情况； 3、本次股东大会以现场投票及网络投票相结合的方式召开。 一、会议召开和出席情况 证券代码：000953 证券简称：河化股份 公告编号：2023-031 （一）会议召开情况 1、召开时间： （1）现场会议召开时间：2023 年 9 月 12 日 （星期二）14:30 （2）网络投票时间： A、通过深圳证券交易所交易系统进行网络投票，时间为 2023 年 9 月 12 日 9:15-9:25，9:30-11:30，13:00-15:00； B、通过互联网投票系统（http://wltp.cninfo.com.cn）进行网络投票，时 间为 2023 年 9 月 12 日 9:15-15:00 之间的任意时间。 2、现场会议召开地点：宁波市江北区人民路 132 号银亿外滩大厦 28 楼会议 室。 3、会议召开方 ...

Financial Performance - The company's operating revenue for the first half of 2023 was ¥111,495,001.53, representing an increase of 18.72% compared to ¥93,912,016.56 in the same period last year[25]. - The net profit attributable to shareholders of the listed company decreased by 78.18% to ¥356,658.48 from ¥1,634,818.67 in the previous year[25]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥544,314.27, a significant increase of 116.29% compared to a loss of ¥3,340,425.88 in the same period last year[25]. - Basic and diluted earnings per share both decreased by 77.78% to ¥0.0010 from ¥0.0045 in the same period last year[25]. - The company reported a total profit of ¥754,299.40, a significant decline of 75.2% from ¥3,033,844.18 in the first half of 2022[133]. - The comprehensive income for the current period is CNY 590,111.63, compared to CNY 1,999,808.03 in the same period last year, indicating a decrease of approximately 70.5%[143]. Cash Flow and Investments - The net cash flow from operating activities was ¥1,685,641.76, down 86.40% from ¥12,395,475.38 in the previous year[25]. - The net increase in cash and cash equivalents was negative at ¥-2,779,232.88, a decline of 109.26% compared to the previous year[45]. - The cash flow from investment activities showed a net outflow of ¥4,405,627.69, compared to a net inflow of ¥17,542,602.30 in the first half of 2022[138]. - Cash received from tax refunds was ¥436,952.04, down from ¥2,502,372.12 in the previous year, indicating a decrease of 82.5%[138]. - The company reported cash outflows for employee payments totaling ¥12,956,390.60, an increase of 6.3% from ¥12,192,234.30 in the same period last year[138]. Assets and Liabilities - Total assets at the end of the reporting period were ¥290,238,680.79, an increase of 1.23% from ¥286,706,539.83 at the end of the previous year[25]. - Total liabilities increased to CNY 194,976,587.27 from CNY 192,258,417.77, marking a growth of approximately 0.9%[129]. - The company's equity attributable to shareholders increased to CNY 78,405,721.41 from CNY 77,839,963.09, a rise of approximately 0.7%[129]. - The total owner's equity as of June 30, 2023, was CNY 95,262,093.52, compared to CNY 94,448,122.06, indicating a growth of about 0.9%[129]. Business Operations - The main business activities include the research, production, and sales of pharmaceutical intermediates and the commissioned processing and sales of urea[31]. - The pharmaceutical intermediate business generated a revenue of 39.2191 million yuan, a significant year-on-year growth of 62.08%[41]. - The urea business reported a revenue of 71.5864 million yuan, reflecting a year-on-year increase of 3.87%[42]. - The company completed the development of 9 projects and has 3 projects under research, with 5 pilot projects completed and 4 small-scale projects finished[43]. - The company has established long-term cooperation with major raw material suppliers to mitigate the impact of seasonal fluctuations in raw material supply[34]. Environmental and Safety Management - The company emphasizes environmental, health, and safety (EHS) management across all business operations, enhancing sustainable development[39]. - The company has a waste gas treatment facility with a design capacity of 15,000 m³/h for workshop 1 and 25,000 m³/h for workshop 2, ensuring compliance with emission standards[76]. - The company reported no significant environmental violations during the reporting period, maintaining compliance with pollution discharge standards[73]. - The company has established a self-monitoring plan and has reported no exceedances in pollutant levels during monitoring[79]. Shareholder and Governance - The company emphasizes the protection of shareholder rights, particularly for minority shareholders, and maintains transparent communication through various channels[81]. - The company has not engaged in any significant litigation or arbitration matters during the reporting period[90]. - The company has not reported any non-operating fund occupation by controlling shareholders or related parties[86]. - The total number of ordinary shareholders at the end of the reporting period is 24,007[114]. - The largest shareholder, Ningbo Yinyi Holdings Co., Ltd., holds 23.76% of the shares, totaling 87,000,000 shares, which are currently frozen[114]. Research and Development - Research and development expenses increased by 46.99% to ¥2,891,612.18, primarily due to an increase in R&D projects[45]. - The company continues to focus on the research and development of chemical raw materials and biopharmaceuticals, aiming to enhance its market position[150]. Financial Reporting and Compliance - The financial report for the first half of 2023 has not been audited[125]. - The financial statements comply with the relevant accounting standards and accurately reflect the company's financial position as of June 30, 2023[157]. - The company’s financial statements are prepared based on the going concern assumption, with no significant doubts regarding its ability to continue operations[156].

广西河池化工股份有限公司 2023 年第一季度报告 证券代码：000953 证券简称：河化股份 公告编号：2023-017 广西河池化工股份有限公司 2023 年第一季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 重要内容提示： 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整，不存在虚假记载、误导性陈述或重 大遗漏，并承担个别和连带的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季度报告中财务信息的真实、准确、完 整。 3.第一季度报告是否经审计 □是 否 1 广西河池化工股份有限公司 2023 年第一季度报告 一、主要财务数据 （一） 主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □是 否 | | 本报告期 | 上年同期 | 本报告期比上年同期增减（%） | | --- | --- | --- | --- | | 营业收入（元） | 57,808,350.06 | 40,969,366.74 | 41.10% | | 归属于上市公司股东的净利润（元） | -1, ...

证券代码：000953 证券简称：河化股份 公告编号：2023-016 广西河池化工股份有限公司 关于举办 2022 年度网上业绩说明会的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整， 没有虚假记载、误导性陈述或者重大遗漏。 广西河池化工股份有限公司（以下简称"公司"）于 2023 年 4 月 20 日在巨潮资讯网（www.cninfo.com.cn）披露了《2022 年年度报告》及 《2022 年年度报告摘要》。 二、投资者问题征集 为提升公司与投资者交流的针对性和有效性，现就公司本次业绩说 明会提前向投资者公开征集问题，广泛听取投资者的意见和建议，投资 者可于网上业绩说明会开始前 5 个交易日内登录深圳证券交易所"互动 易"平台"云访谈"栏目（http://irm.cninfo.com.cn），进入问题征集 页面提出问题。公司将在本次业绩说明会上，对投资者普遍关注的问题 进行回答。 欢迎广大投资者积极参与。 特此公告。 广西河池化工股份有限公司董事会 2023 年 4 月 25 日 为便于广大投资者进一步了解公司 2022 年度经营情况，公司定于 2023 年 5 月 9 日通过深圳证券 ...

Financial Performance - The company's operating revenue for 2022 was ¥160,612,375.12, a decrease of 1.02% compared to ¥162,273,039.66 in 2021[23]. - The net profit attributable to shareholders was -¥100,436,899.14, representing a decline of 1,102.53% from a profit of ¥10,018,330.39 in the previous year[23]. - The net cash flow from operating activities was ¥799,521.87, down 88.09% from ¥6,710,748.57 in 2021[23]. - The basic earnings per share were -¥0.27, a decrease of 1,000.00% compared to ¥0.03 in 2021[23]. - Total assets at the end of 2022 were ¥286,706,539.83, a reduction of 27.67% from ¥396,411,315.40 at the end of 2021[23]. - The net assets attributable to shareholders decreased by 56.13% to ¥77,839,963.09 from ¥177,419,002.38 in 2021[23]. - The company reported a significant decline in both net profit and cash flow, indicating potential challenges in sustaining operations[23]. - The company has faced uncertainty regarding its ability to continue as a going concern, as indicated by the audit report[23]. Revenue Breakdown - The company's total revenue for Q1 2022 was approximately ¥40.97 million, while Q2 revenue increased to ¥52.94 million, followed by a decline to ¥37.98 million in Q3 and further down to ¥28.72 million in Q4[28]. - The net profit attributable to shareholders was negative in all quarters, with Q1 at -¥1.43 million, Q2 at ¥3.07 million, Q3 at -¥5.73 million, and Q4 at -¥96.34 million[28]. - The net cash flow from operating activities showed a positive trend in Q1 and Q2 at ¥3.25 million and ¥9.14 million respectively, but turned negative in Q3 and Q4, recording -¥8.86 million and -¥2.74 million[28]. - The company's revenue from the pharmaceutical intermediates segment was CNY 50,256,563.62, a decrease of 43.97% year-on-year, with a gross margin of 20.84%[52]. - The fertilizer business generated revenue of CNY 109,535,068.83, an increase of 60.39% year-on-year, with a gross margin of 1.27%[52]. - Domestic sales accounted for 86.96% of total revenue, amounting to CNY 139,672,115.12, reflecting a 24.15% increase year-on-year[52]. Research and Development - The company plans to increase investment in R&D and market expansion to diversify its product offerings and explore new fields, particularly in CDMA projects[35]. - The company has maintained a strong focus on R&D, with a dedicated team working on new product development and process optimization[44]. - Research and development expenses decreased by 44.45% to CNY 4,279,280.23 due to a reduction in R&D projects[60]. - The company plans to develop new processes for the synthesis of dezocine intermediates, aiming for industrial production to expand its product range[61]. - The company invested a total of ¥34,365,988.23 in the construction of a multifunctional pilot workshop, achieving 100% completion but with no realized revenue yet[75]. Corporate Governance - The company held three shareholder meetings during the reporting period, ensuring equal rights for all shareholders, especially minority shareholders[92]. - The company has established an independent financial department with a complete financial accounting system, ensuring no interference from the controlling shareholder in financial activities[96]. - The company has established a sound corporate governance structure, continuously improving its governance level in compliance with relevant laws and regulations[94]. - The board of directors actively participated in meetings, with no director raising objections to company matters during the reporting period[120]. - The company has implemented strict insider information management to prevent any leakage of sensitive information during reporting periods[95]. Environmental Responsibility - The company holds a valid Pollutant Discharge Permit, effective from April 10, 2021, to April 9, 2026[137]. - The company has achieved zero exceedance in pollutant emissions throughout the year, as confirmed by self-monitoring reports[141]. - The company has been rated as an environmentally friendly enterprise by the Chongqing Ecological Environment Bureau during the reporting period[144]. - The company has invested approximately CNY 390,000 in optimizing and upgrading its waste gas treatment facilities and wastewater treatment station during the reporting period[143]. - The company has implemented a two-level spray adsorption + low-temperature plasma + activated carbon adsorption process for its waste gas treatment facilities[143]. Shareholder Information - The company has a total of 30,776 shareholders at the end of the reporting period, with significant shareholders including Ningbo Yinyi Holdings with 23.76% and Guangxi Hechi Chemical Industry Group with 10.24%[192]. - The company reported that 87,000,000 shares held by Ningbo Yinyi Holdings are pledged, and 37,493,589 shares held by Guangxi Hechi Chemical Industry Group are frozen[192]. - The total remuneration for directors, supervisors, and senior management during the reporting period amounted to CNY 241.03 million[117]. - The company has not proposed any cash dividend distribution during the reporting period, despite having a positive profit available for distribution to shareholders[129]. - The company has not reported any risks during the supervisory activities of the board of supervisors in the reporting period[125]. Strategic Initiatives - The company plans to enhance R&D investment to develop new products and improve profitability, aiming to accelerate the trial production of the multifunctional pilot workshop project[85]. - The company aims to maintain its market share in existing products while expanding into new customer segments and optimizing product structure[84]. - The company is considering strategic acquisitions to enhance its product portfolio, with a budget of CNY 500 million allocated for potential mergers and acquisitions[110]. - The management emphasized a commitment to sustainability, aiming for a 25% reduction in carbon emissions by 2025[110]. - The company plans to enhance its digital marketing strategy, expecting a 30% increase in online sales channels by the end of 2023[110].

证券代码：000953 证券简称：*ST 河化 广西河池化工股份有限公司投资者关系活动记录表 编号：2021-002 | --- | --- | --- | --- | --- | |------------------|----------------------------------------------------|---------------------------------------------------------------------------------------------|-------------|----------------------| | | | | | | | 投资者关系活动 | □特定对象调研 | □分析师会议 | | | | 类别 | □媒体采访 □业绩说明会 | | | | | | □新闻发布会 □路演活动 | | | | | | □现场参观 | | | | | | ■其他（参加 2021 | 年广西辖区上市公司投资者网上集体接待 | | | | | 日暨 2020 | 年度业绩说明会活动） | | | | 参与单位名称及 | 参加 2021 | 年广 ...

广西河池化工股份有限公司 2022 年第三季度报告 证券代码：000953 证券简称：河化股份 公告编号：2022-070 广西河池化工股份有限公司 2022 年第三季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 重要内容提示： 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整，不存在虚假记载、误导性陈述或重 大遗漏，并承担个别和连带的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季度报告中财务信息的真实、准确、 完整。 3.第三季度报告是否经过审计 □是 否 1 广西河池化工股份有限公司 2022 年第三季度报告 一、主要财务数据 （一） 主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 | | 本报告期 | 本报告期比上年 | | 年初至报告期 末比上年同期 | | --- | --- | --- | --- | --- | | | | 同期增减 | 年初至报告期末 | | | | | | | 增减 | | 营业收入（元） | 37,976,698.50 | -5. ...

广西河池化工股份有限公司 2022 年半年度报告全文 广西河池化工股份有限公司 2022 年半年度报告 2022 年 8 月 1 广西河池化工股份有限公司 2022 年半年度报告全文 第一节 重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容 的真实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担 个别和连带的法律责任。 公司负责人施伟光、主管会计工作负责人卢勇帐及会计机构负责人(会计 主管人员)雷吉声明：保证本半年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本报告的董事会会议。 本半年度报告中如果有涉及未来计划等前瞻性的描述不构成公司对投资 者的实质承诺，投资者及相关人士均应当对此保持足够的风险认识，并且应 当理解计划、预测与承诺之间的差异。 公司已在本报告中详细描述存在的药品带量采购政策影响风险、汇率波 动风险、环保相关风险等。敬请查阅"第三节管理层讨论与分析"中"十、公司 面临的风险和应对措施"部分的内容。 公司计划不派发现金红利，不送红股，不以公积金转增股本。 （三）报告期内在中国证监会指定报刊上公开披露过的所有公司文件的正本及公告原稿。 ...